$599

Amgen and Dexcom Q1 ’26 Earnings; Zealand to Elect Camilla Sylvest to Board; Esperion Gets Acquired; Senseonics Announces $80M Public Offering; Ozempic Pill Launches in US

A series of cardiometabolic-related news items has been observed from Amgen, Dexcom, Zealand Pharma, Esperion Therapeutics, Senseonics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here